Access to conjugate vaccines is limited due to centralized production and cold chain distribution requirements. To combat these challenges, researchers developed a modular technology for in vitro bioconjugate vaccine expression in portable, freeze-dried lysates.
This paper discusses scientific and policy issues related to vaccine platforms, and how they are understood in government, academia, and industry.
Using computer modelling, researchers were able to identify new drugs by building a reliable replica of the bacterial protein and then working out what the best orientation is for the drug to fit in the bacterial protein.
Machine-learning model could help chemists make molecules with higher potencies, much more quickly.
Biomedical research follows a predictable pattern of growth and maturation, and that few new medicines are successfully developed before this research passes a critical established point.
GE Healthcare is launching a ready-to-run “factory-in-a-box” to accelerate the production of viral vector–based therapeutics, including viral vector–based vaccines and oncolytic viruses.
This event features nearly 400 presentations by leaders in pharmaceuticals, academia, and government showcasing case studies, cutting edge data, and insight and perspective. Conference programs include protein and antibody engineering, cancer immunotherapy, oncology, and emerging therapeutics.
Researchers have developed technology to 3D print drugs.
The US Defense Advanced Research Program Agency (DARPA) put out a call for researchers to figure out a process for making at least 1,000 antimicrobial doses to potentially any pathogen within a week of its discovery.